![Berg will partner with Massachusetts General Hospital and Brigham and Women's Hospital to study potential biomarkers for Alzheimer's and other neurodegenerative disorders from Harvard Biomarker Study biospecimens. [Source: ajcity.net]](https://www.clinicalomics.com/wp-content/uploads/2019/01/1397-218x150.jpeg "Genetic Link between Alzheimer’s and Brain Inflammation Found")
EMBL-EBI Launches Free Genetic Disease Diagnostic Software
Researchers at the University of Edinburgh and the European Bioinformatics Institute at the European Molecular Biology Laboratory (EMBL-EBI) have introduced a new diagnostic genome-wide...
Are Dogs the New Early Cancer Detection Tool?
A dog’s sense of smell—more than 10,000 times more sensitive than that of our own—has been exploited by humans for centuries. Whether it is...
Five-Year Super Successes in Genomics and Precision Medicine
Multidimensional, computationally rich approaches represent the next wave of innovation, taking personalized medicine to the next level, while demanding more of practitioners, who in...
Clinical Urologists Group Supports Genomic Testing for Prostate Cancer
AACU statement encourages use of tissue-based molecular testing and/or germline testing for three groups of prostate cancer patients
Former Foundation Medicine Execs Join Hopkins Kimmel Directors, VCs in New Company
Steven Kafka, Ph.D., the former president and chief operating officer of Foundation Medicine who left the company last year, has joined with former colleagues...
Triple Negative Breast Cancers Activate Resistance Pathway to Evade Chemotherapy
Triple-negative breast cancers (TNBCs) are particularly aggressive, metastatic and resistant to chemotherapy treatments. Researchers at the University of Texas MD Anderson Cancer Center have...
Risk Score May Point to Which Breast Cancer Patients Can Avoid Chemo
Researchers have developed a test that predicts the likelihood that a person with invasive lobular breast cancer (ILC) will benefit from chemotherapy. The findings...
8 Companion Diagnostic Developers Making a Mark
If companion diagnostics (CDx) were people, they would be old enough to drink. The first CDx won FDA approval in 1998, when Dako Denmark...
Single Gene Deletion Halts Pancreatic Cancer in Mice
The deletion of the ataxia-telangiectasia group D-complementing (Atdc) gene, whose human homolog is up-regulated in the majority of pancreatic cancer cases, completely prevents the development of tumors in mice.
Exclusive: A Conversation with David Bentley, VP and Chief Scientist, Illumina
From Guy's Hospital in London and the Sanger Centre during the Human Genome Project to one of the first to join early sequencing company Solexa and its subsequent acquisition by Illumina, David Bentley has seen clinical genomics come full circle.
